Indications for: Nateglinide
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
Not for treatment of type 1 diabetes or diabetic ketoacidosis.
Take 1–30mins before meals; skip dose if meal is skipped. 120mg 3 times daily. If near glycemic goal, initially 60mg 3 times daily.
Increased risk of hypoglycemia with changes in physical activity, meal patterns, renal or hepatic impairment: monitor glucose more frequently and may need to adjust dose. Reduced symptomatic awareness of hypoglycemia in longstanding diabetes, diabetic nerve disease, or recurrent hypoglycemia. Moderate-to-severe hepatic impairment. Pregnancy (Cat.C). Nursing mothers: not recommended.
Increased hypoglycemia with concomitant other antidiabetic agents, NSAIDs, salicylates, MAOIs, non-selective β-blockers, anabolic hormones, guanethidine, and CYP2C9 inhibitors (eg, amiodarone, fluconazole, voriconazole, sulfinpyrazone), alcohol; may need dose reduction and monitor. May be antagonized by thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogs (eg, lanreotide, octreotide), and CYP inducers (eg, rifampin, phenytoin, St John's Wort); may need dose increase and monitor. β-blockers, clonidine, guanethidine, reserpine may mask hypoglycemia.
Upper RTI, back pain, flu symptoms, dizziness, arthropathy, diarrhea; hypoglycemia, weight gain.
Formerly known under the brand name Starlix.